Cargando…

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

Detalles Bibliográficos
Autores principales:	McConnell, Scott A, Desai, Dharmik N, Faldu, Sejal P, Hard, Marjie L, Wehr, Angela Y, Weiden, Peter J, von Moltke, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513837/ https://www.ncbi.nlm.nih.gov/pubmed/28744131 http://dx.doi.org/10.2147/NDT.S143337

Ejemplares similares

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2018)

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
por: Hard, Marjie L., et al.
Publicado: (2018)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
por: Hard, Marjie L., et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
por: Weiden, Peter J., et al.
Publicado: (2020)

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
por: Hard, Marjie L., et al.
Publicado: (2017)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison
por: Harlin, Matthew, et al.
Publicado: (2023)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman, Phyllis M, et al.
Publicado: (2017)

Comment on “Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison” [Letter]
por: Rege, Bhaskar, et al.
Publicado: (2023)

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2021)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
por: Yoon, Seonghae, et al.
Publicado: (2014)

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
por: Gutiérrez, Lilia, et al.
Publicado: (2012)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State
por: Shin, Wonsuk, et al.
Publicado: (2023)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis
por: Ow, Randall A., et al.
Publicado: (2022)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction
por: Raish, Mohammad, et al.
Publicado: (2018)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo, Rosaria, et al.
Publicado: (2019)

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011)

Comparative Study on Pharmacokinetics of Four Long-Acting Injectable Formulations of Enrofloxacin in Pigs
por: Ahmad, Salah Uddin, et al.
Publicado: (2021)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Alternative starting regimen with aripiprazole long-acting treatments, a case report
por: Huete Naval, M., et al.
Publicado: (2022)

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study
por: Nasrallah, Henry A., et al.
Publicado: (2021)

Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses
por: Zozaya, Heidi, et al.
Publicado: (2013)

Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers
por: Dai, Xiaoshu, et al.
Publicado: (2021)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug
por: Rohde, Morten, et al.
Publicado: (2014)

Mass balance and pharmacokinetics of an oral dose of (14)C‐napabucasin in healthy adult male subjects
por: Dai, Xiaoshu, et al.
Publicado: (2021)

S206. ARIPIPRAZOLE LONG-ACTING INJECTABLE IN SCHIZOPHRENIA DURING PREGNANCY: A CASE REPORT
por: Sole, Eva, et al.
Publicado: (2020)

Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report
por: Fernández-Abascal, Blanca, et al.
Publicado: (2021)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
por: McEvoy, Joseph P., et al.
Publicado: (2021)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
por: Kawai, Akito, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dnsdbo2o351afc4muid6l75eti